Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:827-832

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rhaleb, N.-E.
Right arrow Articles by Carretero, O. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rhaleb, N.-E.
Right arrow Articles by Carretero, O. A.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow ACE/Angiotension receptors
Right arrow Cell signalling/signal transduction
Right arrow Receptor pharmacology

(Hypertension. 2001;37:827.)
© 2001 American Heart Association, Inc.


Scientific Contributions

Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on DNA and Collagen Synthesis in Rat Cardiac Fibroblasts

Nour-Eddine Rhaleb; Hongmei Peng; Pamela Harding; Mahmoud Tayeh; Margot C. LaPointe; Oscar A. Carretero

From the Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Mich.

Correspondence to Nour-Eddine Rhaleb, PhD, Education and Research Suite 7015, Henry Ford Hospital, Hypertension and Vascular Research Division, 2799 West Grand Boulevard, Detroit, MI 48202-2689. E-mail nrhaleb1{at}hfhs.org

N-Acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a natural inhibitor of pluripotent hematopoietic stem cell entry into the S phase of the cell cycle and is normally present in human plasma. Ac-SDKP is exclusively hydrolyzed by ACE, and its plasma concentration is increased 5-fold after ACE inhibition in humans. We examined the effect of 0.05 to 100 nmol/L Ac-SDKP on 24-hour 3H-thymidine incorporation (DNA synthesis) by cardiac fibroblasts both in the absence and presence of 5% FCS. Captopril (1 µmol/L) was added in all cases to prevent the degradation of Ac-SDKP. Treatment of cardiac fibroblasts with 5% FCS increased thymidine incorporation from a control value of 12 469±594 to 24 598±1051 cpm (P<0.001). Cotreatment with 1 nmol/L Ac-SDKP reduced stimulation to control levels (10 373±200 cpm, P<0.001). We measured hydroxyproline content and incorporation of 3H-proline into collagenous fibroblast proteins and found that Ac-SDKP blocked endothelin-1 (10-8 mol/L)–induced collagen synthesis in a biphasic and dose-dependent manner, causing inhibition at low doses, whereas high doses had little or no effect. It also blunted the activity of p44/p42 mitogen-activated protein kinase in a biphasic and dose-dependent manner in serum-stimulated fibroblasts, suggesting that the inhibitory effect of DNA and collagen synthesis may depend in part on blocking mitogen-activated protein kinase activity. Participation of p44/p42 in collagen synthesis was confirmed, because a specific inhibitor for p44/p42 activation (PD 98059, 25 µmol/L) was able to block endothelin-1–induced collagen synthesis, similar to the effect of Ac-SDKP. The fact that Ac-SDKP inhibits DNA and collagen synthesis in cardiac fibroblasts suggests that it may be an important endogenous regulator of fibroblast proliferation and collagen synthesis in the heart. Ac-SDKP may participate in the cardioprotective effect of ACE inhibitors by limiting fibroblast proliferation (and hence collagen production), and therefore it would reduce fibrosis in patients with hypertension.


Key Words: amino acid • angiotensin-converting enzyme inhibitors • fibroblasts • collagen • endothelin • protein kinases




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y.-H. Liu, M. D'Ambrosio, T.-d. Liao, H. Peng, N.-E. Rhaleb, U. Sharma, S. Andre, H.-J. Gabius, and O. A. Carretero
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin
Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H404 - H412.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C.-X. Lin, N.-E. Rhaleb, X.-P. Yang, T.-D. Liao, M. A. D'Ambrosio, and O. A. Carretero
Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1253 - H1261.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
U. Sharma, N.-E. Rhaleb, S. Pokharel, P. Harding, S. Rasoul, H. Peng, and O. A. Carretero
Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1226 - H1232.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. A. Cavasin, T.-D. Liao, X.-P. Yang, J. J. Yang, and O. A. Carretero
Decreased Endogenous Levels of Ac-SDKP Promote Organ Fibrosis
Hypertension, July 1, 2007; 50(1): 130 - 136.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Peng, O. A. Carretero, T.-D. Liao, E. L. Peterson, and N.-E. Rhaleb
Role of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline in the Antifibrotic and Anti-Inflammatory Effects of the Angiotensin-Converting Enzyme Inhibitor Captopril in Hypertension
Hypertension, March 1, 2007; 49(3): 695 - 703.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. K. Sen, S. Khanna, and S. Roy
Perceived hyperoxia: Oxygen-induced remodeling of the reoxygenated heart
Cardiovasc Res, July 15, 2006; 71(2): 280 - 288.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. Fleming
Signaling by the Angiotensin-Converting Enzyme
Circ. Res., April 14, 2006; 98(7): 887 - 896.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. Omata, H. Taniguchi, D. Koya, K. Kanasaki, R. Sho, Y. Kato, R. Kojima, M. Haneda, and N. Inomata
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Ameliorates the Progression of Renal Dysfunction and Fibrosis in WKY Rats with Established Anti-Glomerular Basement Membrane Nephritis
J. Am. Soc. Nephrol., March 1, 2006; 17(3): 674 - 685.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
I. Ignjacev-Lazich, E. Kintsurashvili, C. Johns, O. Vitseva, A. Duka, S. Shenouda, I. Gavras, and H. Gavras
Angiotensin-converting enzyme regulates bradykinin receptor gene expression
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1814 - H1820.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Peng, O. A. Carretero, N. Vuljaj, T.-D. Liao, A. Motivala, E. L. Peterson, and N.-E. Rhaleb
Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action
Circulation, October 18, 2005; 112(16): 2436 - 2445.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
F. Bouzeghrane, D. P. Reinhardt, T. L. Reudelhuber, and G. Thibault
Enhanced expression of fibrillin-1, a constituent of the myocardial extracellular matrix in fibrosis
Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H982 - H991.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Pokharel, P. P. van Geel, U. C. Sharma, J. P.M. Cleutjens, H. Bohnemeier, X.-L. Tian, H. Schunkert, H. J.G.M. Crijns, M. Paul, and Y. M. Pinto
Increased Myocardial Collagen Content in Transgenic Rats Overexpressing Cardiac Angiotensin-Converting Enzyme Is Related to Enhanced Breakdown of N-Acetyl-Ser-Asp-Lys-Pro and Increased Phosphorylation of Smad2/3
Circulation, November 9, 2004; 110(19): 3129 - 3135.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Wang, O. A. Carretero, X.-Y. Yang, N.-E. Rhaleb, Y.-H. Liu, T.-D. Liao, and X.-P. Yang
N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo
Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2099 - H2105.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. A. Cavasin, N.-E. Rhaleb, X.-P. Yang, and O. A. Carretero
Prolyl Oligopeptidase Is Involved in Release of the Antifibrotic Peptide Ac-SDKP
Hypertension, May 1, 2004; 43(5): 1140 - 1145.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
F. Yang, X.-P. Yang, Y.-H. Liu, J. Xu, O. Cingolani, N.-E. Rhaleb, and O. A. Carretero
Ac-SDKP Reverses Inflammation and Fibrosis in Rats With Heart Failure After Myocardial Infarction
Hypertension, February 1, 2004; 43(2): 229 - 236.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Peng, O. A. Carretero, D. R. Brigstock, N. Oja-Tebbe, and N.-E. Rhaleb
Ac-SDKP Reverses Cardiac Fibrosis in Rats With Renovascular Hypertension
Hypertension, December 1, 2003; 42(6): 1164 - 1170.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C.-M. Cheng, H.-J. Hong, J.-C. Liu, N.-L. Shih, S.-H. Juan, S.-H. Loh, P. Chan, J.-J. Chen, and T.-H. Cheng
Crucial Role of Extracellular Signal-Regulated Kinase Pathway in Reactive Oxygen Species-Mediated Endothelin-1 Gene Expression Induced by Endothelin-1 in Rat Cardiac Fibroblasts
Mol. Pharmacol., May 1, 2003; 63(5): 1002 - 1011.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
K. Kanasaki, D. Koya, T. Sugimoto, M. Isono, A. Kashiwagi, and M. Haneda
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Inhibits TGF-{beta}-Mediated Plasminogen Activator Inhibitor-1 Expression via Inhibition of Smad Pathway in Human Mesangial Cells
J. Am. Soc. Nephrol., April 1, 2003; 14(4): 863 - 872.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Pokharel, S. Rasoul, A. J.M. Roks, R. E.W. van Leeuwen, M. J.A. van Luyn, L. E. Deelman, J. F. Smits, O. Carretero, W. H. van Gilst, and Y. M. Pinto
N-Acetyl-Ser-Asp-Lys-Pro Inhibits Phosphorylation of Smad2 in Cardiac Fibroblasts
Hypertension, August 1, 2002; 40(2): 155 - 161.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
F. Zannad, B. Dousset, and F. Alla
Treatment of Congestive Heart Failure: Interfering the Aldosterone-Cardiac Extracellular Matrix Relationship
Hypertension, November 1, 2001; 38(5): 1227 - 1232.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N.-E. Rhaleb, H. Peng, X.-P. Yang, Y.-H. Liu, D. Mehta, E. Ezan, and O. A. Carretero
Long-Term Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on Left Ventricular Collagen Deposition in Rats With 2-Kidney, 1-Clip Hypertension
Circulation, June 26, 2001; 103(25): 3136 - 3141.
[Abstract] [Full Text] [PDF]